Resultados: 29

“Smart” analysis of the landmark trial - early outcomes with latest generation tavi valves in patients with a small aortic annulus

JACC cardiovasc. interv; 18 (4 Suppl. S), 2025
BACKGROUND Among patients with severe aortic stenosis (AS) un- dergoing transcatheter aortic valve implantation (TAVI), nearly one third have a small aortic annulus. These patients are at higher risk of prosthetic valve dysfunction. Recently, the SMART trial reported that the self-expanding Evolut series...

Early outcomes of the novel Myval THV series compared to SAPIEN THV series and Evolut THV series in individuals with severe aortic stenosis

EuroIntervention; 21 (2), 2025
BACKGROUND: There are limited head-to-head randomised trials comparing the performance of different transcatheter heart valves (THVs).AIMS: We aimed to evaluate the non-inferiority of the balloon-expandable Myval THV series compared to the balloon-expandable SAPIEN THV series or the self-expanding Evolut...

Characteristics and clinical outcomes in patients deemed ineligible for TAVR

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has emerged as a standard therapy for patients (pts) with severe symptomatic aortic stenosis (AS). Its indications have expanded from high-surgical to low-surgical risk pts. However, some pts may be not eligible for the procedure due to clinical a...

Mid-term outcomes following transcatheter aortic valve replacement with meril myval

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
BACKGROUND: TAVR has emerged as a revolutionary treatment for patients with symptomatic and severe AS, irrespective of surgical-risk scores. Novel transcatheter heart valves (THV) with a lower profile, easy of use and expected longer durability are being developed to target younger patients. Myval is a 1...

Conduction disturbances and permanent pacemaker implantation after myval transcatheter heart valve or contemporary standard valves (Sapien and Evolut) implantation: insights from the LANDMARK Trial

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND LANDMARK was a multicenter randomized trial that demonstrated noninferiority of the Myval balloon-expandable trans. catheter heart valve (THV) compared with the contemporary THVs (Sa- pien and Evolut series) at 30 days in patients with severe aortic stenosis. METHODS From January 2021 to Decem...

Predictors of conduction system disturbances resulting in a new permanent pacemaker implantation within the Landmark Trial

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND The need for permanent pacemaker implantation (PPMI) after transcatheter aortic valve implantation (TAVR) is a serious complication that adds additional risk for the patient. It also lengthens the hospitalization and increases costs. Unknown is the PPMI rate of the new balloon expandable Myval...

Clinical impact of sex differences and procedural setting in transcatheter aortic valve implantation

BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a well-established treatment for symptomatic patients with aortic stenosis. Yet, the impact of sex differences and public vs. private procedural setting on TAVI outcomes remain uncertain. METHODS: The RIBAC-NT (Brazilian Registry for Evaluatio...

TAVI-in-TAVI de salvamento por fratura de folheto: relato de caso
Salvage TAVI-in-TAVI for leaflet fracture: case report

Arq. bras. cardiol; 121 (9 supl.1), 2024
INTRODUÇÃO: A longa experiência em troca valvar cirúrgica nos ensinou acerca da durabilidade limitada de biopróteses. E assim como estas, as próteses implantadas via transcateter degeneram com o tempo, requerendo intervenção adicional. O desafio torna-se ainda maior quando a indicação do proced...

Comunicação interatrial como causa de baixo fluxo e baixo gradiente na estenose aórtica grave: uma associação pouco descrita
Interatrial communication as a cause of low flow and low gradient in severe aortic stenosis: an association little described

ABC., imagem cardiovasc; 37 (3 supl. 1), 2024
APRESENTAÇÃO DO CASO: Paciente do gênero feminino, 75 anos de idade, com diagnóstico de Comunicação Interatrial do tipo Ostium Secundum (CIA OS) desde os 65 anos, encontrava-se em acompanhamento ambulatorial, inicialmente assintomática. Nas últimas consultas, queixando-se de dispneia classe funci...

Troca valvar aórtica transcateter e doença arterial coronária – experiência de um centro terciário de cardiologia
Transcatheter aortic valve replacement and coronary artery disease – experience from a tertiary cardiology center

INTRODUÇÃO: A troca valvar aórtica transcateter (TAVI) está estabelecida para o tratamento da estenose aórtica, independente do risco cirúrgico. Estudos demonstram prevalência variável de doença arterial coronária (DAC) nesta população, podendo chegar a até 81% dos pacientes tratados. A pres...